Xofluza Dosing for Children with Acute Influenza
For children ≥12 months old with acute influenza, Xofluza (baloxavir marboxil) is dosed as a single oral dose based on body weight: 2 mg/kg for children weighing <20 kg, 40 mg for those 20 to <80 kg, and 80 mg for those ≥80 kg, administered within 48 hours of symptom onset. 1
Age and Weight-Based Dosing Algorithm
Children 12 months to <12 years:
- Weight <20 kg: 2 mg/kg as a single oral dose 1, 2
- Weight 20 to <40 kg: 40 mg as a single oral dose 3
- Weight ≥40 kg: Follow adolescent/adult dosing below 3
Adolescents ≥12 years and Adults:
- Weight 40 to <80 kg: 40 mg as a single oral dose 4, 3, 1
- Weight ≥80 kg: 80 mg as a single oral dose 4, 3, 1
Critical Formulation Availability Issue
The oral suspension formulation required for children <20 kg was NOT available in the United States for the 2023-2024 influenza season, and availability for 2024-2025 remains uncertain. 5, 1 This severely limits the practical use of Xofluza in younger children who meet the age criteria but fall below the 20 kg weight threshold. 5
Administration Requirements
Food and Supplement Restrictions:
Baloxavir must NOT be taken with dairy products, calcium-fortified beverages, or supplements containing calcium, iron, magnesium, selenium, or zinc, as these dramatically reduce drug absorption and efficacy. 1 Patients should avoid these products for several hours before and after the dose. 1
Route of Administration:
- Can be given orally or via feeding tube without loss of effectiveness 1
- Administered as a single dose (major compliance advantage over 5-day oseltamivir regimen) 5
Timing of Treatment
Initiate treatment within 48 hours of symptom onset for optimal efficacy. 5, 1 This narrow therapeutic window is critical for achieving benefit. 5
Contraindications and Special Populations
Absolute Contraindications:
- Children <12 months old: Not FDA-approved for this age group 3, 1
- Severely immunocompromised patients: Should not receive baloxavir as monotherapy due to resistance risk 1
- Pregnant or breastfeeding women: Use is not advised 1
Renal and Hepatic Impairment:
Clinical Efficacy Considerations
Comparative Effectiveness:
- Similar time to symptom alleviation compared with oseltamivir in pediatric patients 5, 7
- Superior efficacy for influenza B infections compared with oseltamivir in randomized controlled trials 5
- More rapid viral load reduction than oseltamivir 5, 8
Pediatric-Specific Safety Signals:
In children <6 years, post-hoc analyses from Japanese studies showed symptom recurrence after day 4 in 54.5% and fever recurrence in 50% of treated children. 5, 1 This warrants close monitoring in younger pediatric patients, though the medication remains well-tolerated overall. 7, 2
Common Pitfalls to Avoid
Do not prescribe for children <20 kg if the oral suspension formulation is unavailable—only tablets are currently accessible in most U.S. settings 5, 1
Do not administer with dairy or polyvalent cation supplements—this is a critical drug interaction that nullifies efficacy 1
Do not delay treatment beyond 48 hours of symptom onset—efficacy diminishes significantly after this window 5, 1
Do not use as monotherapy in severely immunocompromised patients—resistance emergence is a documented concern 1
When to Choose Baloxavir Over Oseltamivir
Consider baloxavir as an alternative to oseltamivir when:
- Compliance with a 5-day, twice-daily regimen is a concern 5
- Poor tolerance of multiple-dose antiviral regimens 5
- Influenza B infection is confirmed or suspected 5
- Patient/family preference for single-dose therapy 5
However, oseltamivir remains the first-line agent for most pediatric patients, particularly those <5 years old, given the broader evidence base and lack of formulation barriers. 5